Compare DLHC & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLHC | FBIO |
|---|---|---|
| Founded | 1969 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.6M | 88.7M |
| IPO Year | N/A | N/A |
| Metric | DLHC | FBIO |
|---|---|---|
| Price | $5.55 | $3.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 29.9K | ★ 491.9K |
| Earning Date | 02-04-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $344,497,000.00 | $62,303,000.00 |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | $62.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $1.33 |
| 52 Week High | $8.45 | $4.20 |
| Indicator | DLHC | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.83 | 67.88 |
| Support Level | $5.50 | $2.49 |
| Resistance Level | $5.65 | $3.75 |
| Average True Range (ATR) | 0.18 | 0.21 |
| MACD | -0.07 | 0.07 |
| Stochastic Oscillator | 6.17 | 69.57 |
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.